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The calcium ion (Ca2) is a ubiquitous second messenger that is
crucial for the regulation of a wide variety of cellular processes. The
diverse transient signals transduced by Ca2 are mediated by
intracellular Ca2-binding proteins, also known as Ca2 sensors. A
key obstacle to studying many Ca2-sensing proteins is the diffi-
culty in identifying the numerous downstream target interactions
that respond to Ca2-induced conformational changes. Among a
number of Ca2 sensors in the eukaryotic cell, calmodulin (CaM) is
the most widespread and the best studied. Employing the mRNA
display technique, we have scanned the human proteome for
CaM-binding proteins and have identified and characterized a
large number of both known and previously uncharacterized
proteins that interact with CaM in a Ca2-dependent manner. The
interactions of several identified proteins with Ca2CaM were
confirmed by using pull-down assays and coimmunoprecipitation.
Many of the CaM-binding proteins identified belong to protein
families such as the DEADH box proteins, ribosomal proteins,
proteasome 26S subunits, and deubiquitinating enzymes, suggest-
ing the possible involvement of Ca2CaM in different signaling
pathways. The selection method described herein could be used to
identify the binding partners of other calcium sensors on the
proteome-wide scale.
mRNA display  binding motif  protein–protein interactions  calcium-
dependent
Calmodulin (CaM) is a small ubiquitously expressed EF-handCa2-binding protein that mediates a wide variety of cellular
functions in eukaryotes (1–7). Like many other Ca2-binding
proteins, Ca2-loaded CaM has a distinctly different conforma-
tion from the Ca2-free form (7). Ca2CaM can bind to many
different protein targets with high affinity (8–11). After decades
of work, many Ca2CaM-binding proteins have been identified,
including Ca2CaM-dependent protein kinases and phospha-
tases, proteins involved in second-messenger generation, and
proteins that regulate cytoskeletal elements (12, 13). Intrigu-
ingly, protein targets of CaM continue to be discovered (10, 11,
14–16). The identification of CaM-binding targets significantly
advances our understanding of many signaling transduction
pathways mediated by this crucial Ca2-sensing protein.
A key obstacle to studies on Ca2-sensor proteins is the
difficulty in identifying their downstream targets because of the
technical limitations of various methods that have been used,
especially on a proteome-wide scale. Phage display has been used
to isolate CaM-binding sequences from short synthetic peptide
libraries, but the selected CaM-binding sequences were poorly
correlated with naturally occurring proteins (17). Yeast two-
hybrid analysis is another method that is widely used to study
protein–protein interactions. Recently, the yeast two-hybrid
system has been used in a high throughput mode to construct
comprehensive protein–protein interaction maps for several
organisms, including the unicellular yeast Saccharomyces cerevi-
siae (18) and the multicellular organisms Drosophila melano-
gaster (19) and the nematode Caenorhabditis elegans (20). How-
ever, in each of the genome-wide protein–protein interaction
maps, only a limited number of CaM-binding proteins were
reported, and most of the known CaM-binding proteins are
missing. Proteome chips have also been used as a high through-
put approach to identifying protein–protein interactions. In-
deed, a yeast proteome chip has been used to identify CaM-
binding proteins (21). However, the preparation of a proteome
chip from any multicellular organism is a major undertaking. So
far, the conventional SDSPAGE gel overlay with recombinant,
radiolabeled CaM is still the most commonly used method for
the identification and characterization of CaM-binding proteins,
although it is time-consuming and the number of CaM-binding
proteins it can reveal is limited (11, 15). Therefore, new meth-
odologies are necessary to identify the downstream binding
partners of CaM. mRNA display is a relatively new technology
that circumvents a number of difficulties associated with yeast
two-hybrid and phage display (22–24). Because of the covalent
linkage between the genotype and the phenotype, mRNA dis-
play provides a powerful means for reading and amplifying a
protein sequence after it has been selected from large libraries
(1012 to 1013 different sequences).
In this article, we describe the use of this amplification-based
in vitro protein selection technique to identify a large number of
known and previously uncharacterized Ca2CaM-binding pro-
teins from the human proteome.
Materials and Methods
Construction of cDNA Library and Generation of an mRNA-Displayed
Proteome Library.Poly(A) mRNAs from different human tis-
sues, including the brain, heart, spleen, thymus, and muscle
(Stratagene) were mixed as a pool. A cDNA library was
constructed as detailed in Supporting Materials and Methods,
which is published as supporting information on the PNAS web
site. The mRNA-displayed proteome library was generated as
described in refs. 23 and 25. The resulting mRNA-displayed
proteome library was then successively purified on the basis
of the E and FLAG affinity tags at the N and C termini,
respectively.
Selection of Ca2-Dependent CaM-Binding Proteins from mRNA-
Displayed Human Proteome Library. The general selection scheme
is given in Fig. 1. The purified mRNA-displayed proteome
library (1.5 pmol each round) was first diluted in the selection
buffer (50 mM TrisHCl, pH 7.5150 mM KCl0.05% Tween
201 mg/ml BSA5 mM 2-mercaptoethanol0.5 mM Ca2) and
passed through a precolumn of 100 l of streptavidin beads
(Pierce). The flowthrough was incubated with 25 g of biotin-
ylated CaM (Supporting Materials and Methods) for 1 h at 4°C.
After binding, the mixture was incubated with 100 l of pre-
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washed streptavidin beads for another 30 min, followed by
loading into an empty column. Unbound and nonspecifically
bound molecules were washed off the column by using 18 column
volumes of selection buffer. Molecules that bound to CaM in a
Ca2-dependent manner were eluted by using the same buffer
containing 2 mM EGTA. The selected molecules were PCR-
amplified for the next round of selection or cloned into a TOPO
vector (Invitrogen) for sequencing and analysis.
In Vitro CaM-Binding Assay and Affinity Measurement. Individually
cloned sequences selected from round 1 or round 2 were
PCR-amplified and used as a template for a coupled in vitro
transcriptiontranslation reaction in the presence of 10 Ci (1
Ci  37 GBq) [35S]methionine (PerkinElmer) in a total volume
of 25 l for 90 min at 30°C. The expressed protein fragment or
full-length protein was purified by using a Ni2-nitrilotriacetic
acid (NTA) (Qiagen, Valencia, CA) or Co2-NTA (Clontech)
column. Selected fragments were used for the measurement of
binding affinity as follows. An aliquot of purified protein frag-
ment was mixed with an appropriate amount of biotinylated
CaM (from 1 nM to 2.5 M final concentration) in CaM-binding
buffer A (25 mM TrisHCl, pH 8.0150 mM NaCl1 mg/ml
BSA5 mM 2-mercaptoethanol1 mM CaCl2) for 90 min at 4°C.
After binding, 30 l of a 50% slurry of streptavidin beads was
added, and the mixture was incubated for 45 min at room
temperature with gentle mixing. The supernatant was removed
by centrifugation in an Ultrafree-MC centrifugal filter tube
(Millipore). The beads were washed three times with 150 l of
buffer A. Proteins captured were then released from the column
by chelating Ca2 with 150 l of elution buffer containing 2 mM
EGTA. The extent of binding was determined by scintillation
counting each fraction, including the recovered beads. To de-
termine the binding affinity, the data were fit to a binding curve
by using the SIGMAPLOT (Systat, Point Richmond, CA) software.
Cell Culture and Mouse Brain Lysate Preparation. HeLa S3 cells were
grown to stationary phase in Ham’s F12 medium supplemented
with 10% FBS. Cells were harvested and lysed as described in ref.
26. To prepare mouse brain lysates, the brains of 8- to 10-month-
old mice were homogenized in cold lysis buffer immediately after
decapitation. After centrifugation to remove intact cells, the
supernatants were cleared at 21,000  g for 15 min at 4°C. The
lysates that were prepared were used for pull-down assays or
coimmunoprecipitation.
CaM-Sepharose Pull-Down Assay. Approximately 100 l of pre-
equilibrated CaM-Sepharose 4B beads (Amersham Pharmacia)
were added to the lysate (1 mg of total protein), followed by
incubation for 4 h at 4°C in a buffer containing 50 mM TrisHCl
(pH 7.4), 150 mM NaCl, EDTA-free protease inhibitors (Roche,
Indianapolis), and either 1 mM CaCl2 (buffer B) or 2 mM EGTA
(buffer C). The beads were washed five times with buffer B or
buffer C. Proteins that bound to CaM in a Ca2-dependent
manner were eluted from the beads with buffer C containing 2
mM EGTA. Proteins from each fraction were resolved on
SDSPAGE gels, transferred to a nitrocellulose membrane
(Amersham Pharmacia), and probed with an antibody against
the protein of interest.
Coimmunoprecipitation. Equal amounts of precleared whole-cell
lysate (1 mg of total protein) were incubated with 2 g of
primary antibody (anti-CaM, Santa Cruz Biotechnology) for 4 h
at 4°C in the presence of buffer B or buffer C. Approximately 20
l of preequilibrated protein AG-agarose conjugate was added,
and the mixture was further incubated for 2 h at 4°C with mixing.
The pellet was collected and washed three times with buffer B
or buffer C. After the final wash, Ca2CaM-binding proteins
were eluted from pellets by using buffer C containing 2 mM
EGTA. Different fractions were loaded onto SDSPAGE, fol-
lowed by Western blotting and probing.
Supporting Information. For further information, see Supporting
Sequence Information, Figs. 5–16, and Table 3, which are pub-
lished as supporting information on the PNAS web site.
Results and Discussion
Because random priming was used to initiate first-strand cDNA
synthesis, most sequences in the initial library were out-of-frame
or contained sequences from 5- or 3-UTRs. To generate a high
quality protein library for CaM-binding selection, one round of
preselection by using mRNA display was performed (27) by
successive purification of mRNA-displayed proteins based on
affinity tags at the N and C termini. Because only in-frame
transcripts display the C-terminal affinity tag and internally
initiated transcripts lack the N-terminal tag, sequences with
continuous ORFs were enriched and sequences that contained
frameshifts or untranslated regions were removed during the
preselection process (data not shown). Because the initial library
contained 1012 protein molecules (1.5 pmol), every expressed
gene should be represented by numerous copies of distinct gene
fragments. The possibility of identifying proteins encoded by
rare genes is, therefore, significantly increased. Fig. 1 shows the
general scheme for selecting CaM-binding proteins from the
mRNA-displayed human proteome library. Biotinylated CaM
from bovine brain (Supporting Materials and Methods), which is
identical to human CaM in amino acid sequences, was used as the
target for selection. The formation of Ca2CaMbinding part-
ner complexes was performed in a homogenous solution, and the
complexes were captured by streptavidin-agarose beads. Un-
bound members of the library were washed away, whereas
molecules that bound to CaM in a Ca2-dependent manner were
specifically eluted by using an elution buffer containing EGTA.
The enriched library was then regenerated by PCR, in vitro
transcription, crosslinking, in vitro translation and fusion, reverse
transcription, and affinity purifications before it was used for the
subsequent round of selection (23, 28). Approximately 0.25% of
the input of radiolabeled, mRNA-displayed protein molecules
was specifically eluted from the streptavidin agarose beads in
round 1 by chelating Ca2 with EGTA, and this result increased
to 8.5% in round 2 (Fig. 5).
We first analyzed the selected molecules from round 2 by
cloning and sequencing, followed by BLAST searches to identify
the proteins present in this pool. Among the 77 sequences we
analyzed in round 2, there were 28 distinct sequence clusters,
among which 21 were from known proteins and 7 from hypo-
Fig. 1. Selection of CaM-binding proteins by using an mRNA-displayed
human proteome library. mRNA, green; DNA, red; protein, yellow; puromycin,
blue circle. SA, streptavidin beads.
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thetical or unknown proteins. The pool was dominated by a few
known CaM-binding proteins. Of 77 sequences, 48 were from 6
classes of well known CaM-binding proteins, including different
isoforms (, , , and ) of Ca2CaM-dependent protein
kinases (20 clones), different isoforms (, , and ) of Ca2
CaM-dependent protein phosphatases (9 clones), Ca2-
transporting ATPase (11 clones),  II spectrin (4 clones),
phosphoinositide-3-kinase (3 clones), and myosin heavy
polypeptide 1 (1 clone). All of these sequences contained a
known or putative CaM-binding motif (Figs. 7–16), indicating
that their enrichment was indeed due to their binding to Ca2
CaM.
Because the pool from round 2 was dominated by a small
number of well known CaM-binding proteins, we focused our
effort on analyzing the sequences enriched from the first round
of selection. The sequences selected in round 1 were diverse and
not dominated by any particular proteins. Among 499 clones we
analyzed in round 1, 110 sequences were from 28 known
CaM-binding proteins (Table 3). A number of these proteins
were identified as multiple copies. From the remaining 389
Table 1. Potential previously uncharacterized Ca2CaM-binding
proteins isolated from the first round of selection
Protein Accession no. ID no.
CASP8-associated protein 2 AAH56685 1
F-box only protein 9 NP258442 2
Smcx homolog NP004178 3
Transmembrane protein 10 AAH33737 4
Splicing factor, RS-rich 5 AAH18823 5
Dystonin NP056363 6
Optineurin AAH32762 7
Ribosomal protein S8 NP001003 8
Ribosomal protein S4 AAH10286 9
CDC 37-like 1 AAH14133 10
GNAS complex locus NP000507 11
Programmed cell death 7 NP005698 12
Leucine zipper protein AAL78672 13
Radixin AAH02626 14
General transcription factor II-i NP127494 15
Ubiquitin C-terminal hydrolase UCH37 or
UCHL5
NP057068 16
RAD23 homolog B NP002865 17
CDC5-like AAH01568 18
Kinesin family member 1B NP055889 19
Syntaxin 8 AAP35983 20
Dimethylarginine dimethylaminohydrolase 1 AAH33680 21
A kinase (PRKA) anchor protein 6 NP004265 22
Peptidylglycine -amidating monooxygenase AAP36087 23
SRP 14 kDa AAH71716 24
Zinc finger protein 291 NP065894 25
Dedicator of cytokinesis 3 AAP80572 26
HECT domain and RLD2 NP004658 27
eIF3, subunit 8 NP003743 28
Splicing factor 3b, subunit 1 AAH56155 29
Fat-3 XP061864 30
Synaptopodin 2 XP050219 31
v-Myb myeloblastosis viral oncogene
homolog
XP034274 32
TBC1 domain family, 4 XP375032 33
Stromal antigen 1 NP005853 34
26S subunit, non-ATPase, 12 NP002807 35
DnaJ homolog, subfamily C NP056083 36
Predicted KIAA1345 protein XP106386 37
Matrin 3 NP061322 38
XRCC4 AAH05259 39
FK506 binding protein 3 AAP35550 40
Nesprin 2 NP055995 41
Sorting nexin 6 AAH01798 42
Translationally controlled tumor protein, 1 AAH52333 43
Armadillo repeat containing protein NP060590 44
DEAD box polypeptide 21 NP004719 45
RAN binding protein 2 NP006258 46
Membrane component, surface marker 2 NP114068 47
Nexilin (F actin binding protein) NP653174 48
Transcription factor MRG15-2 AAN65338 49
Table 1. (continued)
Protein Accession no. ID no.
5-Purine nucleotidase, II AAH01595 50
LIM domain only 7 NP005349 51
Chromosome 10 ORF 6 NP060591 52
Lymphocyte antigen 96 AAH20690 53
SNRP polypeptide B NP003083 54
MBIP NP057670 55
MYC binding protein C NP996557 56
RNA polymerase, polypeptide B AAH23503 57
Creatine kinase, mitochondrial 1 NP066270 58
ATRX isoform 1 NP000480 59
Peptidylprolyl isomerase-like 2 AAH28385 60
Acyl-coenzyme A dehydrogenase medium
chain
AAH05377 61
v-AKT 1 NP005154 62
LUC7-like isoform  NP958815 63
HECT domain protein LASU1 BAC06833 64
Nebulin NP004534 65
DEAH box polypeptide 57 NP663621 66
Hypothetical protein FLJ13213 AAH46119 67
Integrin alpha chain,  6 NP000201 68




Dedicator of cytokinesis 11 AAH47713 71
Hypothetical protein FLJ12892 NP073594 72
DEAD box polypeptide 5 AAP35589 73
S100B NP006263 74
Ribosomal protein S15a AAH46113 75
26S subunit, non-ATPase, 2 AAH07897 76
Triadin CAD33526 77
SET translocation AAH32749 78
Restin isoform b NP937883 79
Ubiquitin specific protease-M or USP16 AAH30777 80
Ribosomal protein L22 NP000974 81
Ribosomal protein S14 AAH06784 82
Stromal interaction molecule 2 NP065911 83
Peroxiredoxin 1 NP859048 84
Heart motor protein BAA04656 85
XTP5 AAO85462 86
Nucleolar protein 7, 27 kDa AAH62683 87
Predicted KIAA0522 protein XP291345 88
Phosphatase and actin regulator 4 NP076412 89
Enthoprotin DAA00062 90
MYC binding protein 2 NP055872 91
Zinc finger protein 450 NP055612 92
Dmx-like 1 NP005500 93
Ribosomal protein L13a NP036555 94
Sequestosome 1 AAH19111 95
WD repeat domain 9 isoform B NP387505 96
Methionyl aminopeptidase 2 NP006829 97
Hypothetical protein FLJ30655 BAB70876 98








sequences, we were able to identify 269 annotated or hypothet-
ical unique proteins. We tested whether these selected protein
fragments bound to CaM by using the in vitro CaM-binding assay
described above. A number of positive and negative controls
were tested, and the results confirmed that this method is
suitable for studying the binding between Ca2CaM and pro-
teins of interest (data not shown). Using this binding assay, we
found that almost all of the annotated proteins identified in
round 2 bound to CaM in a Ca2-dependent manner. Among the
269 annotated or hypothetical unique proteins from round 1, we
identified 98 previously uncharacterized CaM-binding protein
fragments (Table 1 and Figs. 2A and 6). Therefore, 42% of
unique proteins identified in round 1 were known or potential
previously uncharacterized CaM-binding proteins. Of the se-
lected proteins that bound to CaM, the interactions were indeed
Ca2-dependent. To test whether the full-length proteins also
bind to CaM as expected, we expressed several proteins of
interest by coupled in vitro transcription and translation and
studied their binding to Ca2CaM by using the same in vitro
assay. Fig. 2B shows that these full-length proteins also bound to
CaM in a Ca2-dependent manner.
The Ca2CaM-binding motifs present in target proteins are
quite diverse and have been grouped into three related classes,
namely the 1-14 motif, the 1-10 motif, and the 1-16 motif, in
addition to the Ca2-independent IQ motif (13, 29). Each group
contains several subclasses. A robust selection strategy should
allow the identification of proteins containing all of these
different classes of CaM-binding motifs. Sequence analysis of
known CaM-binding proteins isolated in our selection demon-
strates that all classes and almost all known subclasses of
CaM-binding motifs were identified by using this strategy. They
include the 1-5-8-14 subclass (titin, plasma membrane calcium
pump, and calcineurin A), the basic 1-8-14 subclass (CaM-
dependent protein kinase IV and smooth muscle myosin light
chain kinase), the 1-8-14 subclass (-fodrin), the 1-14 subclass
(CaMK I), the 1-5-10 subclass (HSP90, phosphatidylinositol
3-kinase), the basic 1-5-10 subclass (CaMK II), the 1-16 class
(CaMKK-), and the IQ or IQ-like class (dynein, myosin,
skeletal muscle myosin heavy polypeptide 2, and type III sodium
channel protein). These results demonstrate that our method
allows efficient identification of Ca2CaM-binding proteins
with various binding motifs from the human proteome.
The ease of mapping the binding motifs is one advantage of
our method. The CaM-binding motif of a selected protein can be
readily mapped by locating the shortest overlapping region from
different selected fragments of the parental protein. Among 499
clones analyzed from round 1, 14 were from -fodrin, a well-
characterized CaM-binding protein. These 14 protein fragments
ranged from 80 to 189 residues and overlapped from
M1158-N1192 (MMPRDETDSKTASPWKSARLMVHTVAT-
FNSIKELN) (Fig. 7). This 34 amino acid fragment is just 14
amino acids longer than the previously mapped CaM-binding
motif of -fodrin (A1169-I1188, italicized) (13). Similar results
were obtained from many other well characterized CaM-binding
proteins (Figs. 8–11). The CaM-binding motifs in the previously
uncharacterized CaM-binding proteins were generally predicted
to contain a positively charged amphiphilic -helix when the
selected sequence fragments were analyzed by using a Web-
based motif analysis program (13).
We determined the binding affinities of a number of selected
CaM-binding proteins by varying the concentration of biotin-
ylated CaM used in the binding assay (Table 2). The binding
affinities we obtained for the known CaM-binding proteins
calcineurin and myosin light-chain kinase were similar to those
reported in refs. 30 and 31). We found that the binding affinities
Fig. 2. In vitro binding analysis of selected proteins with biotin-CaM.
Full-length proteins or fragments were generated by a transcription
translation (TNT) reaction. An aliquot of the TNT mixture was incubated with
an appropriate amount of biotinylated CaM in the presence of 1 mM CaCl2,
followed by mixing with streptavidin-agarose beads. The beads were washed,
and the bound molecules were eluted by using a buffer containing 2 mM
EGTA. (A) Selected protein fragments, showing expressed protein (C) and
eluent (E). The complete fragment binding data corresponding to proteins
listed in Table 1 are provided in Fig. 6. The last three samples (N1-N3) are
negative controls. N1 (similar to cardiac morphogenesis protein) and N2 (MLL3
protein) are two protein fragments that do not bind to CaM in the binding
assays. N3 is a protein fragment from the non-CaM binding region of a known
CaM-binding protein (ATP2B1). (B) Full-length proteins, showing expressed
protein (C), the flowthrough (F), the last wash (W), and the eluent (E). N4,
negative control (KIAA0367 from an irrelevant project). The names of all other
proteins are listed in Table 1 according to their IDs.
Table 2. Binding affinity of some selected previously
uncharacterized CaM-binding protein fragments with Ca2CaM
Protein Accession no. Kd, nM
26S subunit, non-ATPase, 2 AAH07897 11  3
26S subunit, non-ATPase, 12 NP002807 214  40
Armadillo repeat-containing protein NP060590 382  53
ATRX NP000480 1248  250
CDC5-like AAH01568 15  2
Dmx-like 1 NP005500 59  7
Enthoprotin DAA00062 85  16
GTFII-i NP127494 131  30
LIM domain only 7 NP005349 19  13
M phase phosphoprotein 8 AAH03542 36  14
Peptidylglycine -amidating
monooxygenase
AAP36087 9  4
Programmed cell death 7 NP005698 200  27
RAD23B NP002865 20  3
Radixin AAH02626 70  13
Ribsome protein S15a AAH46113 239  120
SRP 14 kDa AAH71716 331  156
Sorting nexin 6 AAH01798 528  74
Splicing factor 3b, subunit 1 AAH56155 703  375
Splicing factor, RS-rich 5 AAH18823 893  646
Synaptopodin 2 XP050219 147  52
TBC1 domain family, 4 XP375032 9  2
Transmembrane protein 10 AAH33737 48  5
Ubiquitin C-terminal hydrolase UCH37
or UCHL5
NP057068 453  211
Zinc finger protein 291 NP065894 1005  153
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of our previously uncharacterized CaM binding proteins ranged
from 5 nM to 2 M, suggesting that CaM-binding proteins with
a wide range of binding affinities could be identified. Interest-
ingly, we found that a number of proteins bound to Ca2CaM
with affinities 300 nM. A recent study has provided evidence
that interactions with Ca2CaM with binding affinities close to
1 M could still be physiologically significant (16).
Interactions between several previously uncharacterized
CaM-binding proteins and CaM were further demonstrated by
CaM-Sepharose pull-down assays. Fig. 3 shows that AKT-1,
CDC5-L, and RAD23B were detected in CaM-Sepharose-bound
proteins in a Ca2-dependent fashion in both mouse brain and
human HeLa cell lysates. When EGTA was present in the
binding buffer, the binding of these proteins to CaM-Sepharose
was totally abolished. We next investigated whether endogenous
CaM and two proteins of interest, AKT-1, and CDC5-L, interact
in vivo by coimmunoprecipitation assays. As shown in Fig. 4,
AKT-1 and CDC5-L were coimmunoprecipitated with Ca2
CaM, indicating that the AKT-1Ca2CaM and CDC5-L
Ca2CaM complexes are indeed present in vivo. Because direct
binding of full-length AKT-1 and CDC5L with CaM has been
demonstrated in vitro (Fig. 2B), the observed interactions with
CaM were presumably direct rather than mediated by other
proteins.
Recent studies imply that Ca2CaM might be a regulator of
AKT activation (32), but it remained unclear as to whether the
interaction of AKT with Ca2CaM is direct or is mediated by an
auxiliary protein. Our results provide strong evidence that Ca2
CaM is a direct regulator of AKT in vivo. Rad23A (hHR23A) and
Rad23B (hHR23B) are two human homologs of the S. cerevisiae
RAD23, which are involved in both nucleotide excision repair and
ubiquitin-mediated proteolysis (33–38). Rad23 proteins contain
UbL and UBA domains that can interact with the proteasome and
multiubiquitin chains, respectively. Recently, it was found that
Rad23 could act as a multiubiquitin chain receptor and is involved
in translocating proteolytic substrates to the proteasome and pro-
moting their degradation. The identification of Rad23B as a
Ca2CaM-binding protein prompted us to speculate that Rad23A
might have a similar function. Indeed, Rad23A bound to CaM in a
pull-down assay (data not shown). These results suggest that
Ca2CaM might play an important role in regulating the multiu-
biquitin chain recognition mediated by Rad23.
A number of the CaM-binding proteins identified in this work
belong to protein families such as the DEADH box proteins,
ribosomal proteins, zinc finger proteins, heat shock proteins, pro-
teasome 26S subunits, and deubiquitinating enzymes. These pro-
teins are involved in diverse pathways, including RNA unwinding
and ubiquitin-mediated protein degradation. DEADH box pro-
teins belong to a rapidly growing family of RNA helicases, which
have been implicated in a number of cellular processes (39, 40). One
of the essential questions that remains to be answered is how the
DEADH-box proteins are regulated at the correct place and time.
Three DEADH box proteins, namely DDX5, DDX21, and
DDX57, were identified as Ca2CaM-binding proteins from our
selection, suggesting a possible link between Ca2 signaling and
RNA unwinding. Indeed, it has been reported that DDX5 (p68
RNA helicase) bound to CaM in a Ca2-dependent fashion and
that this interaction inhibited p68 ATPase activity (41). We found
that the CaM-binding motif involved in this regulation is most likely
a Ca2-dependent positively charged amphiphilic -helix
(227RLIDFLECGKTNLRR) (Fig. 15), rather than a Ca2-
independent IQ-containing sequence (554IQTSFR) as hypothe-
sized in ref. 41. Furthermore, similar Ca2CaM-binding motifs
were also present in the selected fragments of the other two
DEADH proteins, which indicates that the RNA unwinding
activity of these DEADH proteins may also be regulated by their
Ca2CaM-binding motifs.
In addition to Rad23 proteins, several other proteins that are
involved in the ubiquitin-proteasome pathway were also identified
as Ca2CaM-binding proteins, namely proteasome 26S subunits
(PSMD2 and PSMD12) and deubiquitinating enzymes (UCHL5
and UBP-M). These results imply a possible role for CaM in this
important pathway. It has been reported that purified 26S protea-
somes could degrade aged Ca2CaM and native Ca2-free CaM
without ubiquitination (42). One possible explanation is that Ca2-
free or Ca2-loaded CaM binds to some components of the 26S
proteasome and such binding allows its entry into the proteasome
without ubiquitination. It was hypothesized that such components
are most likely located on the ATPase subunits of the 19S regula-
tory particle (42). Our finding that Ca2CaM binds to PSMD2 and
PSMD12 implies that the recognition of CaM by the 26S protea-
some is mediated by non-ATPase rather than by ATPase subunits
of the 19S particle. This result is consistent with the yeast proteome
chip data showing that the RPN11 subunit (the human homolog is
PSMD14) of the 19S regulatory particle is a CaM-binding protein
(21). The finding that at least two deubiquitinating enzymes are
Ca2CaM-binding proteins is intriguing. It has been reported that
UCH37 is the major deubiquitinating enzyme associated with the
26S proteasome in fission yeast (43). UBP-M has been found to be
phosphorylated at the onset of mitosis and dephosphorylated
during the metaphaseanaphase transition (44) in mammalian cells.
It is hypothesized that UBP-M may play an important role in
regulating mitotic chromatin by selectively deubiquitinating one or
more critical proteins that are involved in the condensation of
mitotic chromosomes. Our finding suggests that Ca2CaM could
Fig. 4. Coimmunoprecipitation from HeLa cell lysate of AKT-1 and CDC5-L
with CaM. Equal amounts of precleared HeLa cell lysate were incubated with
anti-CaM antibody in the presence of CaM-binding buffer containing either 1
mM CaCl2 or 2 mM EGTA. The protein complex was captured by protein
AG-agarose conjugate and eluted with buffer C. AKT or CDC5L associated
with CaM was detected by Western blot analysis by using anti-AKT (A) or
anti-CDC5L (B). L, lysate; FT, flowthrough; E, elution of pellets by using buffer
C; W, wash of pellets by using buffer B.
Fig. 3. Calcium-dependent interactions between calmodulin and AKT1,
CDC5-L, and RAD23B. CaM-Sepharose pull-down assays by using mouse brain
lysate (A–C) and human HeLa cell lysate (D–F). Lysates were incubated with
CaM-Sepharose 4B beads in the presence of CaCl2 (Upper) or EGTA (Lower) as
described in the experimental section. L, lysate; FT, flowthrough; E, elution; W,
wash. (A and D) AKT-1. (B and E) CDC5-L. (C and F) RAD23B. Anti-AKT1 and
anti-CaM were from Santa Cruz Biotechnology, anti-CDC5L from BD Bio-
sciences, and anti-RAD23B from Rockland (Gilbertsville, PA).








be involved in regulating the ubiquitin chain degradation by deu-
biquitinating enzymes. In addition, it has been reported that CaM
is reversibly monoubiquitinated by a ubiquitin-calmodulin ligase
in the presence of Ca2, and that monoubiquitination strongly
decreases the biological activity of CaM toward phosphorylase
kinase by reducing its affinity and the maximal degree of activation
(45). An important question is how the monoubiquitination of CaM
is regulated. Our result suggests that CaM deubiquitination could
be catalyzed by deubiquitinating enzymes and that the regulation
of CaM function by monoubiquitination could be biologically
significant.
Some ribosomal proteins have been shown to interact with CaM
(46, 47). We have identified six human ribosomal proteins that
interact with Ca2CaM, including 40S ribosomal proteins RPS4,
RPS8, RPS14, RPS15a, and 60S ribosomal proteins RPL13a and
RPL22. These results provide the basis for further investigation of
how the binding of ribosomal proteins to Ca2CaM modulates
ribosome assembly andor the process of translation.
Based on three published genome-wide protein–protein inter-
action maps, it appears that the yeast two-hybrid approach is not
well suited for identifying Ca2-dependent protein–protein inter-
actions (18–20), presumably because Ca2 levels are tightly regu-
lated in yeast (48, 49). Recently, a yeast proteome chip was used to
study interactions of yeast proteins with CaM from bovine brain
(21). From this study, 39 known or potentially uncharacterized
CaM-binding proteins were identified in the yeast proteome. Al-
though the proteome chip approach allows high throughput studies
on protein–protein interactions, preparation of a proteome chip
from any multicellular organism is very time-consuming and chal-
lenging. The mRNA-display approach described herein has the
great advantage of using cellular mRNAs from any organism. Our
results demonstrate that mRNA display can be used to efficiently
map protein–protein interactions on a proteome-wide scale and
may be especially useful for conditional interactions, such as
interactions that are dependent on the cellular Ca2 concentra-
tions. Although mRNA display is a powerful method that allows for
efficient enrichment of protein targets by iterative rounds of
selection based on their interaction with a ligand of interest, this
method also has its limitations. The efficiency with which a specific
sequence is selected depends on a number of factors, including its
abundance in the initial mRNA library, the overall efficiency of
amplification, the efficiency of protein expression and mRNA
fusion, and its affinity to CaM. Because of these biases, some
CaM-binding proteins may not be identified. In addition, protein
fragments rather than full-length proteins are selected. Thus, other
approaches should be used to confirm that the identified interac-
tions occur under physiological conditions. Nevertheless, the use of
the mRNA-display approach has contributed to the comprehensive
cataloging of Ca2CaM-binding proteins. The selection method-
ology described herein could be applied to the high throughput
identification of binding partners of different calcium sensors on a
proteome-wide scale. Furthermore, this method facilitates the
mapping of the binding motifs and interaction sites, which are
important in understanding protein–protein interaction networks.
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